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Available online 22 June 2016Quantiﬁcation of the antigens hemagglutinin and neuraminidase in inﬂuenza vaccines has been reported using
an antibody-free liquid chromatography–mass spectrometry (LC–MS) based method known as MSE “Hi3”. This
approach is based on the average signal intensity of the three most intense tryptic peptides relative to a primary
standard. This strategy assumes that the Hi3 signal responses are consistent for all proteins, and therefore com-
parable to a spiked reference for absolute quantiﬁcation. This method is much faster than the current standard
methods; however, the results can vary signiﬁcantly which brought the method’s accuracy into question. To ad-
dress this question we generated synthetic proteins comprising a concatenation of the peptides used to quantify
the proteins of interest (QconCAT). Complete tryptic digestion of a QconCAT protein produces equal molar pep-
tide amounts, allowing veriﬁcation of equal signal response of Hi3 peptides for the proteins of interest. The gen-
eration of an intact, stable, QconCAT protein that digest completely is challenging. We have designed and
analyzed ﬁve QconCAT proteins with unique design elements to address these challenges. We conclude that a
suitableQconCAT protein can be produced and that the results obtained reinforce the validity of theHi3 approach
for quantifying proteins in annual inﬂuenza vaccine formulations.
Signiﬁcance: The advances in quantitative proteomics have allowed the adaptation and application of these
methods to numerous ﬁelds. In this paper we have validated a Hi3 approach to augment the antigen quantiﬁca-
tion for inﬂuenza vaccines injected intomanymillions annually. Thismethodology allows analysis ofmultiple an-
tigens simultaneously without the need to generate antibodies. Key circumstances where this is advantageous
are for quantitation of very similar antigens, such as the new quadravalent products and when time is critical
such as in a ﬂu pandemic.
Crown Copyright © 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Quantitative concatemer (QconCAT)1. Introduction
Large scale vaccination programs against inﬂuenza are an ongoing
global effort carried out through cooperation between theWorld Health
Organization andmanynational regulatory authorities. Circulating virus
strains are continually monitored and annual vaccines are designed to
contain antigens against the surface proteins of the three (trivalent) or
four (quadrivalent) varieties predicted to be most prevalent: two type
A inﬂuenza strains and one or two type B inﬂuenza strains. Due to the
global prevalence and low reproduction ﬁdelity of the inﬂuenza virus
[1,2], these surface proteins (hemagglutinin — HA and neuraminidase
— NA) mutate frequently; a process known as “genetic drift”. The con-
tents of the annual vaccine must therefore be adapted each year in
order to offer maximum protection. Currently, quality control testing
for HA in inﬂuenza vaccines is carried out using single-radial-
immunodiffusion (SRID) assays [3–5]. Results are compared to those
generated by reference antigens, which also must be generated eachr B.V. This is an open access article uyear and are quantiﬁed by gel densitometry [6]. These methods have
served adequately for some time; however, the generation and charac-
terization of speciﬁc antibodies and primary reference standards are
time-consuming processes. This necessitates selecting strains for sea-
sonal vaccines far in advance of each “ﬂu season” to allow time for gen-
eration of QC materials prior to manufacturing; leaving vaccines
susceptible to loss of efﬁcacy due to genetic drift in circulating strains.
Many research groups, including ours, have endeavoured to design al-
ternative, faster methods for quality assessment of inﬂuenza vaccines
[7–10] and we have published methods using liquid chromatography
coupled to mass spectrometry (LC–MS) to obtain both strain conﬁrma-
tion and quantiﬁcation of antigens [7,10]. For protein quantiﬁcation, we
employed the “Hi3” protein quantiﬁcation technique originally de-
scribed by Silva and coworkers [11], which has proven useful for
many applications across multiple MS platforms [10,12–16]. Thorough
discussions of quantitative proteomics techniques using isotope-
labeled strategies have also been published by Brun and coworkers
[17,18]. By the “Hi3” approach, the average LC–MS signal intensity
from the three most intense tryptic peptides from any protein is used
to estimate its quantity. These Hi3 values have been shown to be similarnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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therefore the Hi3 value of a protein of interest can be compared to
that of a primary reference protein for absolute quantiﬁcation. We
have demonstrated the linear range of this approach using our sample
preparation method and instrumentation, and have conﬁrmed the esti-
mated accuracy and precision using several protein standards [10].
However, when we quantiﬁed antigens in trivalent inﬂuenza vaccines
by this method, using bovine serum albumin (BSA) as a primary stan-
dard, our measurements frequently differed from expected. In particu-
lar, the Hi3 measurements of hemagglutinin content from the type B
inﬂuenza strain were often N2 fold higher than labeled values [10].
This led us to question whether the Hi3 method is sufﬁciently accurate
for this speciﬁc application.We have therefore endeavoured to synthet-
ically generate quantitative peptides from our proteins of interest at
equal molar concentrations in order to assess their relative Hi3 signal
responses. To this end, we designed and expressed a custom protein
comprising a concatenation of our desired peptides; a so-called
QconCAT [19–24]. Theoretically, complete trypsin digestion of this
QconCAT will yield the quantitative peptides at an equal molar concen-
tration; however, we found that producing a stable, intact QconCATpro-
tein that digests completely is challenging, as has been previously
observed [25,26]. Here we describe ﬁve different QconCAT proteins
we have generated to attempt to address these challenges. We support
our results using a selection of labeled synthetic peptides and report a
QconCAT design strategy that results in a protein that is suitable for
the purposes of this study and provides an approach that should be use-
ful for other applications.
2. Materials and methods
2.1. Selection of peptides for QconCAT
Trivalent inﬂuenza vaccines (2011–2012 and 2014–2015) and pro-
tein standard samples were digested in solution and analyzed by LC–
MSE as previously described [10] and the three or four most intense,
fully tryptic peptides from each protein of interest were selected for in-
clusion in the QconCAT proteins. The proteins represented in the
QconCAT were the three HA and NA subtypes contained in a trivalent
inﬂuenza vaccine along with ovalbumin (a regulated component of in-
ﬂuenza vaccine produced in chicken eggs), bovine serum albumin
(our preferred primary standard) and alcohol dehydrogenase (an alter-
native quantitative standard used with many MSE workﬂows). As men-
tioned, the trivalent inﬂuenza vaccine contains two type A inﬂuenza
strains (H1N1 andH3N2) aswell as a Type B strain, therefore these pro-
teins are referred to as H1, N1, H3, N2, HB, NB, Oval, BSA and ADH. The
speciﬁc arrangement of the quantitative peptides from each protein
varied between the ﬁve iterations of QconCATs produced. The se-
quences of the ﬁve QconCAT proteins were as follows:
QconCAT 1
MGSSHHHHHHHHHHSSGLVPRGSHMDDDDKLVNELTEFAKLGEYGFQ
NALIVRHLVDEPQNLIKDAFLGSFLYEYSRVVGLSTLPEIYEKLPLVGGHEGAG
VVVGMGENVKSISIVGSYVGNRANELLINVKSTQNAIDEITNKMNYYWTLVE
PGDKEQLSSVSSFERMNTQFTAVGKSTQAAIDQINGKIDLWSYNAELLVALE
NQHTIDLTDSEMNKEFSEVEGRWDLFVERLSGAMDELHNEILELDEKLSTHN
VINAENAPGGPYKIVVDYMVQKNLNSLSELEVKTFFLTQGALLNDKYNGIITD
TIKYGNGVWIGRGDVFVIRTLLMNELGVPFHLGTKLVDSVVSWSKVIEGWS
NPKILFIEEGKGVTLLLPEPEWTYPRLNVETDTAEIRYGEAYTDTYHSYANKE
WTYIGVDGPDNNALLKGGLEPINFQTAADQARISQAVHAAHAEINEAGRLTE
WTSSNVMEERNVLQPSSVDSQTAMVLVNAIVFK
QconCAT 2
MGSSHHHHHHHHHHSSGLVPRGSHMDDDDKHVKLVNELTEFAKTCV
RFEKLGEYGFQNALIVRYTRKLKHLVDEPQNLIKQNCRRPIKVVGLSTLPEIYE
KMEKRPVKLPLVGGHEGAGVVVGMGENVKGWKVVKSISIVGSYVGNRADTRDLKSTQNAIDEITNKVNSREGRMNYYWTLVEPGDKITFRELREQLSSVSSFE
RFEIRECRTFFLTQGALLNDKHSNRVLKYNGIITDTIKSWRSFKYGNGVWIGR
TKSDLKSTQAAIDQINGKLNRDTKIDLWSYNAELLVALENQHTIDLTDSEMN
KLFERIEKEFSEVEGRIQDRRPYRTLLMNELGVPFHLGTKQVCRNGRLVDSVV
SWSKEILRTFKVIEGWSNPKSKLLQRLSGAMDELHNEILELDEKVDDRHIRLS
THNVINAENAPGGPYKIGTRSGRIVVDYMVQKSGKATKGVTLLLPEPEWTYP
RLSCRFVKLNVETDTAEIRLMCKVKYGEAYTDTYHSYANKILRLYRGGLEPINF
QTAADQARELIRSLKISQAVHAAHAEINEAGREVVRFEKLTEWTSSNVMEER
KIK
QconCAT 3
MGSSHHHHHHHHHHSSGLVPRGSHMDDDDKASGKLVNELTEFAKAS
GKLGEYGFQNALIVRASGKHLVDEPQNLIKASGKDAFLGSFLYEYSRASGKVV
GLSTLPEIYEKASGKLPLVGGHEGAGVVVGMGENVKASGKSISIVGSYVGNR
ASGKANELLINVKASGKSTQNAIDEITNKASGKMNYYWTLVEPGDKASGKE
QLSSVSSFERASGKMNTQFTAVGKASGKTFFLTQGALLNDKASGKYNGIITDT
IKASGKYGNGVWIGRASGKGDVFVIRASGKSTQAAIDQINGKASGKIDLWSY
NAELLVALENQHTIDLTDSEMNKASGKEFSEVEGRASGKWDLFVERASGKTL
LMNELGVPFHLGTKASGKLVDSVVSWSKASGKVIEGWSNPKASGKILFIEEG
KASGKLSGAMDELHNEILELDEKASGKLSTHNVINAENAPGGPYKASGKIVV
DYMVQKASGKNLNSLSELEVKASGKGVTLLLPEPEWTYPRASGKLNVETDTA
EIRASGKYGEAYTDTYHSYANKASGKEWTYIGVDGPDNNALLKASGKGGLE
PINFQTAADQARASGKISQAVHAAHAEINEAGRASGKLTEWTSSNVMEERA
SGKNVLQPSSVDSQTAMVLVNAIVFKASGK
QconCAT 4
MDDDDKASGKLVNELTEFAKASGKLGEYGFQNALIVRASGKHLVDEPQ
NLIKASGKDAFLGSFLYEYSRASGKVVGLSTLPEIYEKASGKLPLVGGHEGAGV
VVGMGENVKASGKSISIVGSYVGNRASGKANELLINVKASGKSTQNAIDEITN
KASGKMNYYWTLVEPGDKASGKEQLSSVSSFERASGKMNTQFTAVGKASG
KTFFLTQGALLNDKASGKYNGIITDTIKASGKYGNGVWIGRASGKGDVFVIRA
SGKSTQAAIDQINGKASGKIDLWSYNAELLVALENQHTIDLTDSEMNKASGK
EFSEVEGRASGKWDLFVERASGKTLLMNELGVPFHLGTKASGKLVDSVVSW
SKASGKVIEGWSNPKASGKILFIEEGKASGKLSGAMDELHNEILELDEKASGK
LSTHNVINAENAPGGPYKASGKIVVDYMVQKASGKNLNSLSELEVKASGKG
VTLLLPEPEWTYPRASGKLNVETDTAEIRASGKYGEAYTDTYHSYANKASGK
EWTYIGVDGPDNNALLKASGKGGLEPINFQTAADQARASGKISQAVHAAHA
EINEAGRASGKLTEWTSSNVMEERASGKNVLQPSSVDSQTAMVLVNAIVFK
ASGKLEHHHHHH
QconCAT 5
MAGRASGKLGEYGFQNALIVRASGKVVGLSTLPEIYEKASGKEVLVLWGI
HHPSTSADQQSLYQNADAYVFVGSSRASGKIDLWSYNAELLVALENQHTIDL
TDSEMNKASGKLSGAMDELHNEILELDEKASGKTFFLTQGALLNDKASGKTL
LMNELGVPFHLGTKASGKGVTLLLPEPEWTYPRASGKGGLEPINFQTAADQA
RASGKISQAVHAAHAEINEAGRASGKLNVETDTAEIRASGKLVDSVVSWSKA
SGKYNGIITDTIKASGKFTSSANGVTTHYVSQIGGFPDQTEDGGLPQSGRASG
KSTQAAIDQINGKASGKSTQNAIDEITNKASGKLPLVGGHEGAGVVVGMGE
NVKASGKLVNELTEFAKASGKNLNSLSELEVKASGKYGNGVWIGRASGKSG
YSGIFSVEGKASGKYGEAYTDTYHSYAKASGKLTEWTSSNVMEERASGKDAF
LGSFLYEYSRASGKSISIVGSYVGNRASGKMNYYWTLVEPGDKASGKSQQAV
IPNIGFRPRASGKLNWLTHLNFKASGKMNTQFTAVGKASGKANELLINVKAS
GKHLVDEPQNLIKASGKNVLQPSSVDSQTAMVLVNAIVFKASGKGNSAPLIIR
ASGKGWAFDDGNDVWMGRASGKGDVFVIRASGKADTISSQIELAVLLSNEG
IINSEDEHLLALERASGKLAAALEHHHHHH.
2.2. In-house QconCAT construct production
2.2.1. QconCAT 1, 2 and 3
The DNA sequence encoding the QconCAT protein was codon
optimised for expression in E. coli and synthesised (Bio S&T Inc., Lachine,
QC, Canada) with an enterokinase recognition cleavage site at the N-
terminal as well as appropriate sequences for insertion into pET15b10
using Nde1/BamH1 restriction sites. Vector pET15b10 is a modiﬁed ver-
sion of pET15b (Novagen,Merck KGaA, Darmstadt, Germany) where an
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for a total of 10 histidines.
2.2.2. QconCAT 4
QconCAT 4 was identical to QconCAT 3 except that the
polyhistidine tag was moved from the N-terminus to the C-
terminus and reduced from 10 histidines to 6. This was achieved
using primers QconCAT@Nde1 (gcagccatatggatgacgacgacaaag) and
QconCAT@Xho1 (cgctcgagtttgccggacgctttgaaaacaatcgc) to amplify
from construct pET15b10QconCAT3. The insert was introduced into
pET21b from Novagen using restriction sites NdeI and XhoI, creating
pET21b QconCAT 4.
2.2.3. In-house QconCAT expression and puriﬁcation of QconCAT 1, 2, 3 and
4
Plasmids were transformed in a strain of E. coli BL21(DE-3) auxo-
troph for arginine and lysine [27].Expression was carried out by incu-
bating a freshly transformed colony in M9 minimal media
supplemented with 13C labeled arginine and lysine at 37 °C until a cell
density measure at OD600 of 0.8 was obtained. Protein expression
was induced with the addition of 1 mM isopropyl thiogalactoside
(IPTG) and allowed to proceed for 3.5 h at 37 °C. Cells were harvested
by centrifugation and puriﬁed using a standard protocol for IMAC
under denaturing conditions in a 6 M guanidinium chloride (GdmCl)
buffer. Puriﬁed protein samples were dialysed in either water or 0.1%
triﬂuoroacetic acid and concentrations were estimated by absorbance
at OD280.
2.2.4. Commercial production — QconCAT 5
The QconCAT 5 protein was purchased from PolyQuant GmbH (Bad
Abbach, Germany). As per information supplied by PolyQuant, QconCat
production was (in brief) carried out as follows. The appropriate gene
sequence to express the desired polypeptide was codon-optimized
using the Leto algorithm (Entelechon Bioinformatics, Regensburg,
Germany) and subcloned into a pET21a expression vector via NdeI/
BamHI restriction enzyme sites. This construct was then transfected
into E. coli, expressed in arginine and lysine depleted media supple-
mented with 13C labeled arginine and lysine, and puriﬁed via C-
terminal His-tag followed by dialysis into 0.1% formic acid. Quality con-
trol steps performed by the manufacturer included assessment by SDS
PAGE and Coomassie staining, peptide mass ﬁngerprinting by MALDI
ToF analysis of the trypsin digested QconCAT, and quantiﬁcation via
total amino acid analysis. Total yield was ~1.3 mg at a concentration
of 0.26 mg/ml and an estimated purity of N95%.
2.3. Synthetic labeled peptides
The Hi3 peptides for each of the three hemagglutinin proteins
contained in the 2014–2015 trivalent inﬂuenza vaccine, as well as for
BSA, were purchased as synthetic labeled peptides from JPT Peptide
Technologies GmbH (Berlin, Germany). These so-called SpikeTides are
labeled with 13C 15N lysine or arginine residues resulting in a mass in-
crease of approximately 8 or 10 Da respectively. They are also tagged
with a proprietaryUV-adsorbentmoietywhich allows them to be quan-
tiﬁed after production, andwhich is cleaved by trypsin digestion prior to
LC–MS analysis. SpikeTides are therefore designed to be added to pro-
tein samples prior to trypsin digestion to ensure they undergo the
same sample preparation procedure as the analytes being quantiﬁed.
SpikeTides were received lyophilized in vials containing 1 nmol of ma-
terial and were reconstituted as needed in 100 μl of 50 mM NH4HCO3;
generating 10 nmol/ml stock solutions.
2.4. Preparation of working solutions
TheQconCAT proteinswere diluted in 0.05%Rapigest™ SF surfactant
(Waters Ltd.,MA, USA) in 50mMNH4HCO3 to create ~10 μg/mlworkingsolutions. A BSA primary protein standard was purchased from the US
National Institute of Standards and Technology (NIST) and working so-
lution was prepared by diluting to 20 μg/ml ﬁnal concentration in 0.1%
RapiGest. Trivalent inﬂuenza vaccines manufactured for use in the
northern hemisphere in 2011–2012 and 2014–2015 were obtained
from a manufacturer and were mixed 1:1 with BSA working solution
to generate the BSA-spiked vaccine working solutions (10 μg/ml BSA).
An equal volume (10 μl) of each of the 12 SpikeTide stock solutions
were mixed together and added to 120 μl of 0.1% RapiGest in 50 mM
NH4HCO3. This generated a working solution of the 12 SpikeTides,
each at a concentration of 0.42 nmol/ml.
2.5. In-solution trypsin digestion
All digestions were carried out in triplicate. QconCAT Samples were
prepared for analysis by placing 10 μl of QconCAT working solution
along with 10 μl BSA-spiked vaccine working solution into Eppendorf
Lo-Bind 1.5mlmicrocentrifuge tubes. SpikeTide sampleswere prepared
by mixing 5 μl of SpikeTide working solution, 5 μl of 0.05% RapiGest and
10 μl BSA-spiked vaccine working solution. Sample tubes were
suspended in boiling water for 5 min, and then cooled to room temper-
ature prior to the addition of 5 μl trypsin stock (Promega Corp.,Madison,
WI, USA) Sequence Grade, 0.4 μg/μl in 50mMNH4HCO3). Samples were
incubated for 2 h at 37 °C with orbital shaking at 300 rpm in an
Eppendorf Thermomixer (Hamburg, Germany). The digestion was
quenched and the acid-labile RapiGest detergentwas cleaved by the ad-
dition of 10 μl 0.175 M HCl and 35 μl 0.1% formic acid. Samples were
then left at room temperature for 1 h and then at 4 °C overnight, after
which they were centrifuged at 14,000 ×g for 30 min. Supernatant
was mixed 1:1 with 2× injection buffer (6% ACN, 0.4% FA, and 0.1%
TFA in water) and analyzed by LC–MS.
2.6. SDS-PAGE and in-gel trypsin digestion
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) was carried out by mixing QconCAT protein solutions 1:1 with
2× Laemmli buffer (Bio-Rad Laboratories Inc., Hercules, California),
boiling for 5 min, and separating through a 10% polyacrylamide mini-
gel over 60 min at 200 mA. A Bio-Rad Precision Plus™ protein standard
solution was also run for approximate mass measurement of the
QconCAT products. Gels were stained with SYPRO Ruby® ﬂuorescent
stain and photographed, and then lanes were excised using a clean scal-
pel. Bands corresponding in mass to the intact QconCAT protein were
excised, diced into ~1 mm3 pieces and transferred to a 1.5 ml
microcentrifuge tube. The portion of the gel lane below the intact
QconCAT band was cut into six equal-size pieces, which were similarly
diced and a transferred into tubes. The proteins in the diced gel seg-
ments were trypsinized and the resulting peptides were extracted as
follows: To each tube, a 100 μl aliquot of 50 mM NH4HCO3 was added,
samples were vortexed brieﬂy and the liquid was removed and
discarded. Gel pieces were then dehydrated by the addition of 100 μl
of a 50/50 mix of 50 mM NH4HCO3/acetonitrile. Following incubation
for 20 min at room temperature, the solution was discarded and the
gel samples were dried in a vacuum centrifuge for 10 min. Trypsin,
(1 μg in 50 μl of 50 mM NH4HCO3) was added and the samples were
left for 10 min at room temperature, then excess trypsin solution was
removed and discarded, 25 μl of 25 mMNH4HCO3 was added and sam-
ples were digested at 37 °C over 3 h. After digestion, the remaining so-
lution surrounding the gel pieces was transferred into a clean 1.5 ml
microcentrifuge tube. Peptides were then extracted from the gel pieces
by adding 50 μl of 50% acetonitrile, 5% formic acid, incubating for 10min
at room temperature, transferring the solution to the microcentrifuge
tube, and repeating the process one additional time. The resulting pep-
tide solutionswere vacuum-centrifuged until dry, reconstituted in 50 μl
of injection buffer (3% ACN, 0.2% FA, and 0.05% TFA in water) and ana-
lyzed by LC–MS.
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Samples were loaded onto a Waters Symmetry C18 trap column
(180 μm × 20 mm with 5 μm particles) and desalted with 0.1% formic
acid in water (solvent A) for 3 min at 5.0 μl/min. Chromatographic sep-
aration was achieved using a Waters nanoAcquity UPLC with a BEH130
C18 reverse-phase analytical column (100 μm × 100 mm with 1.7 μm
particles) and a linear gradient between solvent A and 0.1% formic
acid in acetonitrile (solvent B). Peptides were eluted at a ﬂow rate of
0.450 μl/min, over a 30 minute linear gradient from 3% to 40% solvent
B. Peptide analysis was carried out by a Waters Synapt HDMS system
(Milford, MA, USA) operating in data independent analysismode. Alter-
nating low and high energy scanswere 0.8 s in duration and covered an
m/z range from 50 to 1990. Trap collision energy was set to 6 V for low
energy scans and ramped from15 to 35V over the course of the high en-
ergy scans. The transfer collision energywas set to 2 V for both high and
low energy scans. Calibration was maintained throughout all analyses
using a lock spray solution containing 100 fmol/μl glu-ﬁbrinopeptide,
which was sampled using one low energy scan every 30 s.
2.8. Data processing and protein quantiﬁcation
Data were processed and searched against two databases using the
Protein Lynx Global Server software platform (PLGS 3.0, Waters Ltd.)
employing default settings and allowing oxidation of methionine and
deamidation of asparagine as variable modiﬁcations and up to 2 missed
trypsin cleavages per peptide. Modiﬁed lysine and arginine residues
found in labeled peptides were also deﬁned and incorporated into
search parameters. Databases contained either the customized QconCat
protein sequence or the full sequences of the proteins represented
therein, alongwith trypsin, several human keratins and, since the virus-
es are grown in chicken eggs, the entire chicken (Gallus gallus) prote-
ome. Protein quantities were calculated as the summed intensity of
the signal generated by the three most intense tryptic peptides from
any protein (Hi3) relative to that of BSA. By default, this includes the
peak intensities from all charge states for the Hi3 peptides; however
we have also manually included peak intensities from both modiﬁed
peptides and in-source fragments. Protein quantities are reported rela-
tive to BSA. Similar sample concentrations and volumes have been
used here as in our earlier work [10] to ensure data arewithin the linear
range of the instrument.Table 1
A summary of the design strategy associated with each QconCAT protein.
Iterationa Design strategy
QconCAT
1
– 4 best-ionizing peptides from each protein.
– Direct concatenation (no linking sequence).
– N-terminal polyhistidine tag.
QconCAT
2
– 3 best-ionizing peptides from each protein.
– All peptides are ﬂanked at the N- and C-terminus by the three
residues found in the native protein sequence.
– Each of these extended peptides is linked to the next by an argi-
nine residue.
– N-terminal polyhistidine tag.
QconCAT
3
– 4 best-ionizing peptides from each protein.
– All peptides are linked by an identical tetrapeptide spacer (ASGK).
– N-terminal polyhistidine tag.
QconCAT
4
– 4 best-ionizing peptides from each protein.
– All peptides are linked by an identical tetrapeptide spacer (ASGK).
– C-terminal polyhistidine tag.
QconCAT
5
– 4 best-ionizing peptides from each protein.
– All peptides are linked by an identical tetrapeptide spacer (ASGK).
– Peptides from each protein strategically dispersed throughout se-
quence rather than grouped together (as was the case in previous
iterations).
– C-terminal polyhistidine tag.
a QconCATs 1–4 contain quantitative peptides identiﬁed from the 2011–2012 trivalent
seasonal inﬂuenza vaccine whereas QconCAT 5 contains those from the 2014–2015 vac-
cine. QconCAT 5 has 8 peptides not contained in QconCATs 1–4.3. Results and discussion
In order to use a QconCAT to test the accuracy of the Hi3 protein
quantiﬁcation method, the synthetic protein, upon digestion, must
yield its constituent peptides in equal molar amounts. Therefore, an op-
timal QconCAT protein should be fully expressed and remain intact dur-
ing expression and puriﬁcation, should digest completely and
reproducibly, and should generate stable, unmodiﬁed peptides. Syn-
thetic peptides used for protein quantiﬁcation are often selected strate-
gically with these criteria in mind. Here, however, the peptides have
been pre-selected solely on the basis of LC–MS peak intensity; having
been identiﬁed as Hi3 quantitative peptides in our earlier work [10].
Ideally, our QconCAT should generate approximately equal Hi3 values
for all proteins represented therein. Our results indicate, however, that
design features such as the location of the puriﬁcation tag, the arrange-
ment of the peptides, and how they are linked together can have a sig-
niﬁcant impact on quantitation. It is important to note that replicate Hi3
quantiﬁcation of a given protein will not always utilize the same trio of
quantitative peptides, particularly for proteins that yield many tryptic
peptides that ionize well. Having more than three possible quantitative
peptides reduces the impact on accuracy if a particular peptide is not
identiﬁed in every replicate, (e.g., due to inconsistencies in sample prep-
aration, LC separation, MS analysis, or data processing). As such, all of
our QconCAT proteins except QconCAT 2 contain the four best-
ionizing peptides from each protein of interest fromwhich the software
selects the Hi3 for quantiﬁcation. The ﬁve QconCAT proteins described
here were designed and produced in succession after examining the re-
sults from analyses of earlier iterations. The design elements incorporat-
ed into each QconCAT protein are outlined in Table 1 and the impact of
the changes are summarized in Table 2.
3.1. QconCAT 1
Our ﬁrst QconCAT iteration is a direct concatenation of the four best-
ionizing peptides from our proteins of interest and is based on
the 2011–2012 trivalent inﬂuenza vaccine. The puriﬁcation tag is
located on the N-terminus and has the amino acid sequence
MGSSHHHHHHHHHHSSGLVPRGSHMDDDDK. It is followed by the
four best ionizing peptides from BSA in order of rank, followed in turn
by peptides from ADH, H1, N1, H3, N2, HB, NB and Oval. Although we
were aware that commercial vendors of QconCAT existed, we estimated
thatwe could generate the product in-house for approximately 1/10 the
costs of purchasing it. We therefore initially chose to generate the
QconCAT proteins ourselves.
All of the expected peptides from QconCAT 1 were successfully
identiﬁed and the averageHi3 value for all proteins represented (relative
to BSA) was close to 1 (0.95). However, the relative standard deviation
(RSD) of the Hi3 values was high (33%) and three peptides were
identiﬁed containing missed cleavages. (A peptide with a missed cleav-
age was ignored if its intensity was b5% of that of the fully cleaved prod-
uct). One of the identiﬁed peptides containing a missed cleavage
(GSHMDDDDKLVNELTEFAK) spans the puriﬁcation tag and the
ﬁrst quantitative peptide for BSA. In triplicate digestions, its average in-
tensity was more than seven times higher than the fully digested
peptide (LVNELTEFAK). This represents a design ﬂaw in the QconCAT
protein; a predictable problem based on earlier work describing inhibi-
tion of trypsin digestion in proximity to aspartic acid (D) and glutamic
acid (E) residues [28]. Clearly, the presence of four aspartic acid residues
on the N-terminal ﬂanking side of the cleavage site severely impeded
trypsin digestion, despite the high enzyme to protein ratio. Another pep-
tide containing a missed cleavage (MNYYWTLVEPGDKEQLSSVSSFER)
spans two quantitative peptide candidates from the H1 protein. In this
case, the direct concatenation of two peptides results in a cleavage site
(K) with an aspartic acid on one side and a glutamic acid on the other.
Again, this environment is predictably unfavourable for tryptic digestion
and the intensity of the missed cleavage peptide was more than three
Table 2
A summary of the results of MS analyses of QconCAT proteins.
Avg Hi3 value rel. to BSA (RSD) Missed cleavages # of quantitative peptides affected by missed cleavages % intact estimatea
QconCAT 1 0.95 (33%) 3 5 Not measured
QconCAT 2 0.69 (24%) 2 2 Not measured
QconCAT 3 0.46 (26%) 1 1 59%
QconCAT 4 1.21 (52%) 1 1 39%
QconCAT 5 0.99 (18%) 0 0 76%
a Values for “% Intact Estimate” are derived from analyses of polyacrylamide gels as discussed.
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similar though less extreme example was observed with the peptide
IDLWSYNAELLVALENQHTIDLTDSEMNKEFSEVEGR, which spans two
quantitative peptides from the H3 protein. Here the lysine residue is
followed by a glutamic acid, though the intensity of the peptide having
a missed cleavage was relatively low; b20% of that of the more intense
of the two fully cleaved peptides. Having identiﬁed these problems
with the trypsin digestion of QconCAT 1, no further analysis of this pro-
tein was carried out. Instead, a new protein (QconCAT 2) was designed
and generated.
3.2. QconCAT 2
The second QconCAT iteration was designed as an attempt to ad-
dress the digestion problems encountered with QconCAT 1. Since
missed cleavages were very rarely observed in our analyses of the anti-
gens in the vaccine, QconCAT 2 was designed to include cleavage sites
ﬂanked by the same sequence as found in the native proteins; a strategy
that has been recently explored and reported [29]. Our expectation was
that this design would create digestion conditions at each cleavage site
in theQconCAT thatwere similar to those found in thenative protein. To
this end, ﬂanking sequences three residues in length, were added to
both the N-terminal and C-terminal end of each peptide. In most
cases, an arginine residue was also added between the C-terminal
ﬂanking region of one peptide and the N-terminal ﬂanking region of
the next. This additional arginine was omitted however, if either of
the ﬂanking regions already contained a trypsin cleavage site. As an ex-
ample, the ﬁrst three quantitative peptides from BSA, which follow the
puriﬁcation tag, were expressed as shown below with ﬂanking regions
in parentheses and the quantitative peptides in bold:
(HVK)LVNELTEFAK(TCV)R(FEK)LGEYGFQNALIVR(YTR)(KLK)HLV
DEPQNLIK(QNC)R(RPI).
In order to offset the mass increase associated with the addition of
the ﬂanking regions, only the three best-ionizing peptides, rather than
four as in QconCAT 1, were included in this iteration. This strategy suc-
cessfully eliminated all themissed cleavages observed inQconCAT 1 and
all expected peptides were identiﬁed. However, two new sites were
generated that demonstrated resistance to trypsin digestion. One of
these missed cleavage sites affected the N-terminus of the third peptide
from BSA, which is shown in the example above. Here, the adjacent
ﬂanking regions result in the sequence YTRKLK preceding the desiredTable 3
Description of the Hi3, QconCAT, and SpikeTides methods for protein quantiﬁcation.
Quantiﬁcation
technique
Method of quantiﬁcation
Hi3 Antigen concentrations are calculated using the ratio of their Hi3
values relative to that of a primary standard (BSA), which is spiked
at a known concentration.
QconCAT Antigen concentrations are calculated using the ratio between the
Hi3 value of native peptides and their labelled counterparts,
which are generated by digestion of an independently quantiﬁed
QconCAT protein (QconCAT 5).
SpikeTides Antigen concentrations are calculated using the ratio between the
Hi3 value of native peptides and their independently quantiﬁed,
synthetic, labeled peptides.peptide, HLVDEPQNLIK. This likely presents too many tryptic cleavage
sites in close proximity for optimal digestion to occur, as has been ob-
served in other studies [28,30]. The result is that the peptide
LKHLVDEPQNLIKQNCR (which has a missed cleavage at both ends) is
observed, though its intensity is only ~20% of that of the fully cleaved
product. The other missed cleavage peptide (IEKEFSEVEGR) represents
an uncleaved ﬂanking region from the N-terminus of an H3 peptide.
Here the cleavage site has an unfavourable glutamic acid on both sides
and the intensity of the peptide containing the missed cleavage is
~80% of that of the fully cleaved peptide. However, this unfavourable se-
quence is identical to that found in the native protein, in which the
missed cleavage peptide it not observed. This suggests that other factors
in the QconCAT sequence beyond the three residue ﬂanking region also
inhibit digestion at this site. While the intensities of the incompletely
digested peptides in QconCAT 2 were much lower than those in
QconCAT 1, we chose to attempt an alternative design strategy to im-
prove trypsin digestion efﬁciency.
3.3. QconCAT 3
For the third QconCAT iteration,we considered onlymaking changes
to the portion of the sequence where missed cleavages were observed.
However we chose to attempt a strategy that would be applicable to
QconCAT proteins in general, rather than only addressing issues with
this speciﬁc sequence. To this end, we designed QconCAT 3 with identi-
cal linkers (ASGK) between each peptide. These linkers were designed
to create similar and favourable digestion conditions at each cleavage
sitewhile limiting the additionalmolecularweight added to theprotein.
QconCAT 3 comprises the four best-ionizing peptides from each protein
and an N-terminal puriﬁcation tag, like QconCAT 1. LC–MS analysis of
QconCAT 3 identiﬁed all the peptides of interest and only one peptide
containing a missed cleavage, LSTHNVINAENAPGGPYKASGK; however
the average Hi3 value (relative to BSA) was very low (0.46) with a
26% RSD. This caused us to question whether our QconCAT proteins
were being produced and puriﬁed intact or if protein fragments were
being generated (e.g., from incomplete translation or from protein deg-
radation). To address this question, we analyzed QconCAT 3 by SDS-
PAGE. The resulting gel had a prominent band at the expectedmolecular
weight of the intact protein, but it also showed a series of faint, diffuse
bands below (Fig. 1). Both the intact band and the remainder of the
gel lane below it were subjected to in-gel trypsin digestion and LC–MS
analysis. The segments of the gel below the intact band were found to
contain fragments of QconCAT 3, predominantly including the N-Table 4
Calculations used to evaluate the accuracy of the QconCAT quantiﬁcation technique.
[QconCAT 5] 13 μg/ml ÷ 73,970 g/mol = 0.18
nmol/ml
Average Hi3 ratio between native and
labeled BSA peptides
0.82
Measured BSA content 0.18 nmol/ml × (0.82) × 69,323
g/mol = 10.2 μg/ml
RSD from triplicate measurements 8.2%
Expected BSA content 10.0 μg/ml
Calculated accuracy of QconCAT
quantiﬁcation
Measured / Expected ± RSD
102 ± 8.2%
Fig. 1. Polyacrylamide gel showing the molecular weight marker (M), and QconCAT 3, 4
and 5. (Samples were run on separate gels and images have been superimposed and
aligned for ease of comparison).
Fig. 3. The peptide arrangements in QconCAT 4 and 5 with ~ representing the “ASGK”
linkers.
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ated with each protein, arranged from N-terminus to C-terminus are
shown in Fig. 2. This suggests that either the protein was not being
completely translated, or that it was degrading prior to the puriﬁcation
step. In either case, digestion of QconCAT 3 in solution would not yield
peptides in equalmolar amounts, butwould be biased towards peptides
closer to the puriﬁcation tag. This explains why the average Hi3 value
was low relative to BSA, whose peptides are adjacent to the puriﬁcation
tag. The LC–MS analysis of the gel bands also allowed us to estimate the
percentage of intact QconCAT. This was calculated as the sum of all
QconCAT peptides identiﬁed in the intact band divided by the sum of
all peptide intensities from the entire gel lane. By this calculation,we es-
timate that QconCAT 3 was 59% intact.
3.4. QconCAT 4
To address the possible problem of incomplete translation, we gen-
eratedQconCAT 4,whichwas identical to QconCAT3 except that the pu-
riﬁcation tag was shortened and moved from the N-terminus to the C-Fig. 2. The relative intensities of peptides identiﬁed in the sections of gel below the intact
protein bands for QconCAT 3 and 4 (grouped by protein). Values are expressed relative to
the protein adjacent to the puriﬁcation tag (BSA inQconCAT 3 and ovalbumin forQconCAT
4). Proteins are ordered on the x-axis from N-terminus to C-terminus.terminus. QconCAT 4 was analyzed in solution and in-gel in a similar
manner to QconCAT 3. Like QconCAT 3, all the expected peptides from
QconCAT 4 were identiﬁed and only one peptide containing a missed
cleavage was identiﬁed. However the average Hi3 value relative to
BSA and the results from the gel analysis were starkly different between
the two. The average Hi3 value for QconCAT 4 was 1.21 and the results
of the PAGE/LC–MS analysis demonstrated a reduced bias towards the
peptides nearer to the tagged terminus of the protein (Fig. 2). However,
the Hi3 values for QconCAT 4 had an RSD of 52% and we estimate (by
our PAGE/LC–MS approach) that only 39% of the protein was intact in
the ﬁnal solution. These results show that placing the puriﬁcation tag
on the C-terminus is important to reduce the bias towards purifying
taggedprotein fragments by ensuring only fully translated proteins con-
tain the polyhistidine group. However, we were not satisﬁed with the
reliability of our Hi3 values given their high RSD and the low estimates
of percent intact protein. We therefore chose to generate QconCAT 5,
again containing design elements aimed at addressing shortcoming in
the earlier iterations. We also chose to engage Polyquant GmbH, a com-
mercial producer of QconCAT proteins, to manufacture QconCAT 5 for
us.
3.5. QconCAT 5
The design of QconCAT 5 incorporates the lessons learned from our
earlier iterations, but contains quantitative peptides from the 2014–
2015 trivalent inﬂuenza vaccine rather the 2011–2012 product in
order to align with other ongoing work (a change affecting 8 of the 36
quantitative peptides). QconCAT 5 includes the “ASGK” spacer between
peptides of interest, has the puriﬁcation tag located on the C-terminus
and comprises the four best-ionizing peptides from the proteins of in-
terest. Unlike the earlier iterations however, the peptides from each
protein represented in QconCAT 5 are strategically dispersed through-
out the sequence, rather than being grouped together. The goal of this
approach is to limit the impact of any bias associated with the location
of the puriﬁcation tag. For example, rather than having all four peptides
from BSA grouped together at the N-terminal end of the protein, they
are spread out throughout the QconCAT sequence. Fig. 3 summarizes
the peptide arrangement for both QconCAT 4 and 5 with BSA peptides
highlighted in bold red.
The results from our analyses of QconCAT 5 were very encouraging.
The average Hi3 value of all the represented proteins, relative to BSA,
was 0.99 with an RSD of 18% and there were no identiﬁed peptides
with missed cleavages having intensities greater than 5% of their fully
digested counterparts. While Fig. 1 shows that QconCAT 5 still contains
protein fragments (similar in appearance to QconCAT 3 and 4) the intact
protein band is larger and more intense in QconCAT 5 than in the two
previous iterations. QconCAT 5 was found to be ~76% intact by our
gel-based method; an improvement from QconCAT 3 and 4. These
Fig. 4. (Left) Measured content of the hemagglutinin antigens in the 2014–2015 inﬂuenza vaccine using Hi3, QconCAT, and SpikeTides quantiﬁcation techniques. (Right) Calculated
accuracies of the QconCAT and SpikeTides quantiﬁcation techniques by measurement of known quantities of the BSA primary standard. Error bars are standard deviations of the
measurements from three preparative replicates.
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equal molar amounts and that the Hi3 values of the proteins of interest
are, in fact, approximately equal.
3.6. Comparison of Hi3, QconCAT and SpikeTides
Having generated a suitable QconCAT, we also purchased three
quantitative peptides from each of the hemagglutinin proteins (H1,
H3 and HB) in the 2014–2015 vaccine as synthetic labeled peptides
(SpikeTides). We were therefore able to compare the quantities of
these antigens in the vaccine asmeasured by three different techniques,
as outlined in Table 3.
The accuracies of the QconCAT and SpikeTides quantiﬁcation tech-
niques were evaluated by using them to measure a known quantity of
the BSA primary reference spiked into a vaccine sample. An example
calculation to evaluate the accuracy of the QconCAT quantiﬁcation tech-
nique is shown in Table 4. In this example, QconCAT 5 and BSA-spiked
vaccine (10 μg/ml BSA) were combined in equal volumes.
The calculated values for hemagglutinin content in a 2014–2015 tri-
valent inﬂuenza vaccine using the three quantitative techniques, (along
with the calculated accuracies of the QconCAT and SpikeTides quantiﬁ-
cation techniques) are shown in Fig. 4.
Fig. 4 shows that the results obtained from the Hi3 and QconCAT
method (using the optimized QconCAT 5 protein) agree very well and
that the estimated accuracy of the QconCAT method is excellent based
on measurements of the BSA primary standard. The calculations from
the SpikeTides technique yield slightly higher average values and
lower reproducibility and estimated accuracy; however, the same rela-
tive trend, with the concentration of HB being approximately twice as
high as H1 and H3 is observed by all three techniques. The higher mea-
sured values and standard deviations obtained by the SpikeTides tech-
nique appear to be due to inconsistencies with detecting some of the
larger synthetic peptides, (e.g., N20 residues in length) either due to
problems with manufacturing, stability, or digestion (data not shown).
These issues were not explored in depth here.
4. Conclusions
Measurement of protein quantity by comparing a protein's Hi3 LC–
MS peptide intensities to those of a primary standard is a rapid and fac-
ile approach to quantitative proteomics. While the accuracy of this ap-
proach is, in general, comparable to most other popular proteomics
quantitative techniques [31,32], it is only suitable for proteins that gen-
erate approximately equal Hi3 signal responses at equal molar concen-
trations. Hi3 may not be an accurate method to quantify proteins that
are extensivelymodiﬁed and/or do not generate a large number of tryp-
tic peptides upon proteolytic digestion.Wehave produced anoptimized
QconCAT protein containing quantitative peptides from proteins of in-
terest from a trivalent inﬂuenza vaccine and have veriﬁed that theirHi3 responses are approximately equal. The details of the QconCAT de-
sign, all the Hi-3 peptides, the analytical details and results from all
methods are included in the Data in Brief article [33]. These results sup-
port the use of theHi3 approach as a valid technique for the quantitative
screening of formulated inﬂuenza vaccines and bulk products. Whereas
the production of antibodies and reference antigens for SRID analysis
takes months, Hi3 analysis can be used to quantify vaccine antigens in
less than a week and requires only a suitable protein standard such as
BSA, which is readily commercially available. Hi3 analysis can also be
used evaluate the reference antigen materials used for SRID, for exam-
ple for consistency between manufacturers. These results also demon-
strate that Hi3 quantiﬁcation is a valuable complementary technique
to SRID, the former measuring total protein content and the latter mea-
suring antigen/antibody binding activity. The Hi3 method is not sensi-
tive to loss of protein activity due to mis-folding or aggregation. It
does, however, allow for concurrent quantiﬁcation of all the protein
contents in an inﬂuenza vaccine, including HA and NA and other pro-
teins of interest such as ovalbumin. Furthermore, this approach should
be broadly applicable to other vaccines and biologics drugs, possibly
contributing towards the development of a standardized platform for
biologic drug testing.4.1. Future work
The data presented here demonstrate that a QconCAT protein can be
used to establish the relative LC–MS signal intensities of different pep-
tides at equalmolar concentrations. In this case, we quantiﬁed inﬂuenza
vaccine proteins using their most intense tryptic peptides, however for
routine annual screening it would be preferable to use peptides that are
highly conserved. This would ensure that the accuracy of the measure-
ments is consistent from year to year and would allow for streamlined
data collection, processing and reporting. To allow this, we envision
generating a QconCAT containing three conserved peptides from each
of the HA and NA subtypes along with three peptides from BSA. Diges-
tion and LC–MS analysis of such a QconCAT would allow us to establish
the relative signal responses of these peptides; values that could be ap-
plied every year for the absolute quantiﬁcation of proteins in inﬂuenza
vaccine samples spiked with BSA.Transparency document
The Transparency document associated with this article can be
found, in online version.Conﬂict of interest
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